Abstract: SA-PO350
Higher Type VI Collagen Formation Is Independently Associated with Increased Risk of Cardiovascular Events and Mortality in the Canagliflozin Cardiovascular Assessment Study (CANVAS)
Session Information
- Hypertension and CVD: Mechanisms
November 09, 2019 | Location: Exhibit Hall, Walter E. Washington Convention Center
Abstract Time: 10:00 AM - 12:00 PM
Category: Hypertension and CVD
- 1403 Hypertension and CVD: Mechanisms
Authors
- Rasmussen, Daniel Guldager Kring, Nordic Bioscience, Herlev, Denmark
- Jatkoe, Timothy, Janssen Research & Development, LLC., Raritan, New Jersey, United States
- Sparding, Nadja, Nordic Bioscience, Herlev, Denmark
- Blair, Joseph Pm, Nordic Bioscience, Herlev, Denmark
- Karsdal, Morten Asser, Nordic Bioscience, Herlev, Denmark
- Gutstein, David E., Janssen Research & Development, LLC., Spring House, Pennsylvania, United States
- Genovese, Federica, Nordic Bioscience, Herlev, Denmark
- Hansen, Michael K., Janssen Research & Development, LLC., Spring House, Pennsylvania, United States
Background
Patients with type 2 diabetes are at significantly higher risk of experiencing cardiovascular complications. It has been shown that type VI collagen (COL VI) is markedly upregulated during pathogenic processes of the heart and vasculature. The role of COL VI biomarkers has been sparsely investigated in relation to cardiovascular events. We evaluated a novel biomarker of COL VI formation as a prognostic marker for cardiovascular events and mortality in patients with type 2 diabetes from the Canagliflozin Cardiovascular Assessment Study (CANVAS).
Methods
COL VI formation was assessed with the PRO-C6 enzyme-linked immunosorbent assay (ELISA), detecting a specific fragment of COL VI released upon deposition in the extracellular matrix. PRO-C6 levels were measured in baseline plasma samples from 3531 patients from CANVAS. Results from Cox proportional hazard regression models were reported as unadjusted or adjusted for the traditional risk factors age, sex, BMI, systolic and diastolic blood pressure, duration of diabetes, LDL cholesterol, HbA1c, eGFR, and albumin/creatinine ratio.
Results
In the unadjusted analysis, levels of PRO-C6 were significantly associated with heart failure (HF), cardiovascular death (CVD), a composite of HF and CVD, and all-cause mortality (Table, all P<0.0001). To assess the independent association of PRO-C6 with these outcomes, the analysis was adjusted for traditional risk factors. In the adjusted analysis, PRO-C6 was significantly associated with the listed outcomes (Table, all P≤0.0001).
Conclusion
In conclusion, this study reveals an independent association of the COL VI biomarker PRO-C6 with cardiovascular events and mortality in the CANVAS study.
Funding
- Commercial Support – Janssen Research & Development, LLC